There is an ongoing randomized phase III clinical trial, PROFILE 1007, comparing crizotinib to standard chemotherapy in the second-line setting for ALK-positive NSCLC patients (Pfizer Inc., 2010). The gene discussed is ALK; the disease is non-small cell lung carcinoma.